ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Clinical trials for ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.

Never miss a new study

Get alerted when new ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

Sign up with your email to follow new studies for ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

Experimental drug offered to lung cancer patients out of options

Disease control NO_LONGER_AVAILABLE

This program provides access to the experimental drug taletrectinib for adults with advanced ROS1-positive lung cancer who have run out of approved treatment options and cannot join regular clinical trials. The drug aims to control cancer growth in patients who have already tried…

Matched conditions: ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Apr 01, 2026 22:11 UTC

ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Get alerted when new ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) trials appear

Experimental drug offered to lung cancer patients out of options